

NCT01214096 Processed comparison:

Summary:
CHIA has 27 criteria while your personal folder has 49 criteria
Total found criteria: 20/27
Total not Found: 7/27
Total Extra: 22
This trial is INVALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Left ventricular ejection fraction (LVEF) ≤ 40%    │ Left ventricular ejection fraction (LVEF) ≤ 40%    │
│ (ECHO)                                             │ (ECHO)                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients with chronic heart failure (NYHA class II │ Patients with chronic heart failure (NYHA class II │
│ or III)                                            │ or III)                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ In the past one month the clinical condition       │ In the past one month the clinical condition       │
│ (including history clinical symptoms and signs)    │ (including history clinical symptoms and signs)    │
│ was relatively stable                              │ was relatively stable                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients on standard treatment of chronic heart    │ Patients on standard treatment of chronic heart    │
│ failure at the target dose or maximum tolerance    │ failure at the target dose or maximum tolerance    │
│ dose for over 1 month or unchanged dose in last 1  │ dose for over 1 month or unchanged dose in last 1  │
│ month                                              │ month                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Understand and sign the informed consent form      │ Understand and sign the informed consent form      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Atrial fibrillation                                │ Atrial fibrillation                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject underwent cardiac pacemaker treatment      │ Subject underwent cardiac pacemaker treatment      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject underwent metal graft treatment            │ Subject underwent metal graft treatment            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Claustrophobia                                     │ Claustrophobia                                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Ischemic heart failure without the                 │ Ischemic heart failure without the                 │
│ revascularization or undergone the                 │ revascularization or undergone the                 │
│ revascularization within last 6 months             │ revascularization within last 6 months             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject underwent cardiac surgery or               │ Subject underwent cardiac surgery or               │
│ cerebrovascular events within the previous six     │ cerebrovascular events within the previous six     │
│ months                                             │ months                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects who plan to have cardiac transplantation  │ Subjects who plan to have cardiac transplantation  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Severe hepatic and renal insufficiency (serum      │ Severe hepatic and renal insufficiency (serum      │
│ creatinine>2 0 mg /dl AST or ALT is five times     │ creatinine>2 0 mg /dl AST or ALT is five times     │
│ higher than the upper limit of normal range)       │ higher than the upper limit of normal range)       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject needs mechanical ventilation               │ Subject needs mechanical ventilation               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Chronic heart failure complicated with acute       │ Chronic heart failure complicated with acute       │
│ hemodynamic disturbance or acute decompensation    │ hemodynamic disturbance or acute decompensation    │
│ within last 1 month                                │ within last 1 month                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Childbearing-aged female subject who is unmarried  │ Childbearing-aged female subject who is unmarried  │
│ or dose not bear child                             │ or does not bear child                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject with life expectancy less than 6 months as │ Subject with life expectancy less than 6 months as │
│ assessed by investigators                          │ assessed by investigators                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject participated in any other clinical trial   │ Subject participated in any other clinical trial   │
│ within the previous three months                   │ within the previous three months                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Examinations (physical examination X-ray           │ Examinations (physical examination X-ray           │
│ examination type-B ultrasonic detection or other   │ examination type-B ultrasonic detection or other   │
│ methods) reveal that the subject has malignant     │ methods) reveal that the subject has malignant     │
│ mass gland hyperplasia or adenoma with endocrine   │ mass gland hyperplasia or adenoma with endocrine   │
│ activity or impact on heart or endocrine function  │ activity or impact on heart or endocrine function  │
│ (such as pheochromocytoma thyroid enlargement)     │ (such as pheochromocytoma thyroid enlargement)     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ The Investigator deemed for whatever reason that   │ The Investigator deemed for whatever reason that   │
│ the subject is not likely to complete the study or │ the subject is not likely to complete the study or │
│ comply with the study procedures (due to           │ comply with the study procedures (due to           │
│ administration or any other reason)                │ administration or any other reason)                │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



╒═════════════════════════════════════════════════════════════════════════════════════════════════╕
│ CHIA Criteria Not Found in Personal                                                             │
╞═════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Age 18-75 years old no limitation in gender                                                     │
├─────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Acute myocardial infarction cardiac ischemia indicated by 6-minute walk test hypertrophic       │
│ cardiomyopathy constrictive pericarditis significant valve disease or congenital heart disease  │
│ severe pulmonary hypertension                                                                   │
├─────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Systolic blood pressure < 90mmHg or > 160mmHg                                                   │
├─────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Mobitz Type II or III° atrial ventricular block，severe ventricular arrhythmia (polymorphic and │
│ frequent premature ventricular beats frequent non-sustained ventricular tachycardia)            │
├─────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Serum potassium<3 2mmol/L or>5 5mmol/L                                                          │
├─────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Female subject is pregnant or plan to become pregnant                                           │
├─────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Subject with previous history of tumor or current tumor patient or subject with pre-cancerous   │
│ disease manifested by pathological examination (such as ductal carcinoma in situ or cervical    │
│ epithelial dysplasia)                                                                           │
╘═════════════════════════════════════════════════════════════════════════════════════════════════╛



╒═════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                                             │
╞═════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Age 18-75 years old                                                                                 │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Mobitz Type II or III° atrial ventricular block                                                     │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ hypertrophic cardiomyopathy                                                                         │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have minimum age of 18 Years                                                                   │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have maximum age of 75 Years                                                                   │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ severe pulmonary hypertension                                                                       │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ significant valve disease                                                                           │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Acute myocardial infarction                                                                         │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ constrictive pericarditis                                                                           │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Serum potassium<3 2mmol/L                                                                           │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ severe ventricular arrhythmia (polymorphic and frequent premature ventricular beats frequent non-   │
│ sustained ventricular tachycardia)                                                                  │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ congenital heart disease                                                                            │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Female subject is pregnant                                                                          │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Systolic blood pressure > 160mmHg                                                                   │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Female subject plan to become pregnant                                                              │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Serum potassium>5 5mmol/L                                                                           │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Systolic blood pressure < 90mmHg                                                                    │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ current tumor patient                                                                               │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ no limitation in gender                                                                             │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Subject with previous history of tumor                                                              │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ subject with pre-cancerous disease manifested by pathological examination (such as ductal carcinoma │
│ in situ or cervical epithelial dysplasia)                                                           │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ cardiac ischemia indicated by 6-minute walk test                                                    │
╘═════════════════════════════════════════════════════════════════════════════════════════════════════╛